Key facts
- OcuDyne’s last known valuation is $41.0M (Mar 2025).
- It has raised $12.6M across 2 recorded rounds; the latest was Early Stage VC ($5.7M) in Feb 2025.
- Notable investors include Inversora Campiezo.
- OcuDyne has filed 2 Form Ds with the SEC since 2019, most recently Mar 2025 ($5.7M sold to 8 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for OcuDyne
Funding rounds
2 roundsAbout OcuDyne
Developer of an ocular perfusion technology designed to treat age-related eye disease. The company's technology treats various ocular health conditions such as blurred vision or a central blind spot by improving blood flow to the eye, enabling patients to get effective treatment for restoring vision loss.
- Sector
- Healthcare
- HQ
- Brooklyn Park, MN, United States
- Founded
- 2013
- Employees
- 2
- Website
- ocudyne.com/
- Ownership
- Privately Held (backing)
OcuDyne doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in OcuDyne shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on OcuDyne in its N-PORT filings yet. We sweep new filings monthly.